Press Releases

Date Title
Toggle Summary Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
SAN DIEGO , July 02, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock, including
Toggle Summary Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
SAN DIEGO , June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a
Toggle Summary Kura Oncology Announces Commencement of Public Offering of Common Stock
SAN DIEGO , June 27, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions,
Toggle Summary Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial
– John Farnam appointed to newly created position of Chief Operating Officer – – Bridget Martell , M.D., and Blake Tomkinson , Ph.D., join as Vice Presidents of Clinical Development – – Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) expected
Toggle Summary Kura Oncology to Present at JMP Securities Life Sciences Conference
SAN DIEGO , June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., Kura’s President and Chief Executive Officer, is scheduled to
Toggle Summary OncoDNA announces screening collaboration with Kura Oncology
- OncoDNA to support patient enrolment for Kura Oncology’s Phase II trial of tipifarnib - Agreement demonstrates OncoDNA’s biopharma partnership strategy GOSSELIES, Belgium , May 22, 2018 (GLOBE NEWSWIRE) -- OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision
Toggle Summary Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) on track to initiate in second half of 2018 – – Data from multiple Phase 2 trials of tipifarnib in solid tumor and hematologic indications anticipated in second half of 2018 – – Company expects
Toggle Summary Kura Oncology to Present at Deutsche Bank 43rd Annual Health Care Conference
SAN DIEGO , May 03, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Deutsche Bank 43rd Annual Health Care Conference .
Toggle Summary Kura Oncology Announces New Patent for Tipifarnib in Hematologic Malignancies
– Newly issued patent expands protection for tipifarnib in U.S., provides exclusivity in certain CXCL12-expressing cancers to 2037 – – Second U.S. patent for tipifarnib reinforces potential for broader strategy to provide commercial exclusivity based upon biomarker-guided development – –
Toggle Summary Kura Oncology to Report First Quarter 2018 Financial Results
SAN DIEGO , May 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2018 financial results after the close of U.S.